Delivery Order SPE2DX22D0020-SPE2D826F06CS

The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $12,762.72 to AmerisourceBergen Drug Corp (UEI: KABZK8W6PQT3) on November 17, 2025, with completion scheduled for November 18, 2025. This competitive award, utilizing firm fixed pricing, was issued under a non-set-aside procurement and represents a child order against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract is for pharmaceutical products and medical supplies to support federal healthcare operations, leveraging AmerisourceBergen's established role as a critical pharmaceutical distributor for military and veteran healthcare systems. As a major healthcare solutions provider headquartered in Conshohocken, Pennsylvania, AmerisourceBergen maintains an extensive portfolio of competitively awarded contracts with the Defense Logistics Agency, delivering brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains.

AmerisourceBergen holds a substantial prime IDC valued at $999,999,999.00 with DLA Troop Support Medical, designated as SPE2DX and extending through December 2026, which serves as the overarching contract vehicle for this delivery order. This comprehensive global pharmaceutical support contract enables the company to supply a broad range of medical commodities to support military healthcare programs worldwide, including customers such as the Defense Health Agency and the U.S. Coast Guard. The current delivery order exemplifies the company's capability to fulfill federal medical procurement requirements through competitive processes and maintain consistent, reliable pharmaceutical supply chains for Department of Defense healthcare operations.